OncLive TV

Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.

Eric A. Klein, MD, discusses the importance of providing genomic testing to patients with prostate cancer.

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Neeraj Agarwal, MD, discusses the FDA approval of olaparib (Lynparza) as a treatment for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment with enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Nizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.

Adilia Hormigo, MD, PhD, discusses the impact of the coronavirus disease 2019 (COVID-19) on high density areas.

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Luis E. Raez, MD, discusses the safety measures that have been put in place at Memorial Cancer Institute in response to the coronavirus disease 2019 (COVID-19) in lung cancer.

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Mark A. Schroeder, MD, discusses the importance of JAK inhibition in graft-versus-host disease (GVHD).

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

Hope S. Rugo, MD, discusses recent updates with immunotherapy in triple negative breast cancer.

Panayiotis S. Savvides, MD, discusses the utility of immunotherapy in lung cancer.

Jennifer Litton, MD, discusses the findings from the overall survival analysis of the EMBRACA trial, the implications of these data, and the future utility of talazoparib in this space.

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Andrew Yee, MD, discusses trials evaluating treatment for patients with lenalidomide-refractory multiple myeloma.

Jessica Donington, MD, MSCR, discusses the role of neoadjuvant immunotherapy in patients with stage II non–small cell lung cancer.

Michael Wang, MD, discusses research trends in mantle cell lymphoma (MCL).

Phillip J. Koo, MD, discusses the need for next-generation imaging in prostate cancer.

Carlos E. Vargas, MD, discusses research with proton therapy in prostate cancer.

Che-Kai Tsao, MD, shares strategies to improve outcomes in renal cell carcinoma.

Betsy O'Donnell, MD, discusses the utility of up-front triplet regimens in multiple myeloma.

Rogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer.